Gavin R Screaton

List of Publications by Year in Descending Order

103 papers	9,915 citations	45 h-index	99 g-index
165 ext. papers	14,496 ext. citations	21.1 avg, IF	5.87 L-index

#	Paper	IF	Citations
103	SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.. *Cell*, **2022**,	56.2	154
102	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.. *Lancet, The*, **2022**,	40	46
101	Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines.. *Nature Medicine*, **2022**,	50.5	11
100	The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies.. *EBioMedicine*, **2022**, 77, 103902	8.8	5
99	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the COV-BOOST trial.. *Journal of Infection*, **2022**,	18.9	7
98	Analysis of SARS-CoV-2 in Nasopharyngeal Samples from Patients with COVID-19 Illustrates Population Variation and Diverse Phenotypes, Placing the Growth Properties of Variants of Concern in Context with Other Lineages.. *MSphere*, **2022**, e0091321	5	0
97	Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum.. *Lancet, The*, **2021**,	40	115
96	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. *Lancet, The*, **2021**,	40	30
95	Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. **2021**,		25
94	Human antibody C10 neutralizes by diminishing Zika but enhancing dengue virus dynamics. *Cell*, **2021**, 184, 6067-6080.e13	56.2	3
93	The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants.. *Cell Host and Microbe*, **2021**,	23.4	14
92	The epitope arrangement on flavivirus particles contributes to Mab C10ß extraordinary neutralization breadth across Zika and dengue viruses. *Cell*, **2021**, 184, 6052-6066.e18	56.2	5
91	An immunodominant NP-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease. *Nature Immunology*, **2021**,	19.1	19
90	Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. *Cell*, **2021**, 184, 5699-5714.e11	56.2	64
89	Anti-spike antibody response to natural SARS-CoV-2 infection in the general population. *Nature Communications*, **2021**, 12, 6250	17.4	13
88	A haemagglutination test for rapid detection of antibodies to SARS-CoV-2. *Nature Communications*, **2021**, 12, 1951	17.4	25
87	Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine. *ACS Central Science*, **2021**, 7, 594-602	16.8	47

86	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. *Nature Communications*, **2021**, 12, 2055	17.4	37
85	The antigenic anatomy of SARS-CoV-2 receptor binding domain. *Cell*, **2021**, 184, 2183-2200.e22	56.2	145
84	Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. *Cell*, **2021**, 184, 2348-2361.e6	56.2	549
83	Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. *Cell*, **2021**, 184, 2201-2211.e7	56.2	269
82	Antibody evasion by the P.1 strain of SARS-CoV-2. *Cell*, **2021**, 184, 2939-2954.e9	56.2	281
81	Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels. *Transfusion Medicine*, **2021**, 31, 167-175	1.3	42
80	Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine **2021**,		13
79	Stringent thresholds in SARS-CoV-2 IgG assays lead to under-detection of mild infections. *BMC Infectious Diseases*, **2021**, 21, 187	4	12
78	Flavivirus maturation leads to the formation of an occupied lipid pocket in the surface glycoproteins. *Nature Communications*, **2021**, 12, 1238	17.4	12
77	An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status. *Clinical Infectious Diseases*, **2021**,	11.6	31
76	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. *Lancet HIV,the*, **2021**, 8, e474-e485	7.8	62
75	Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. *Cell*, **2021**, 184, 4220-4236.e13	56.2	196
74	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). *Lancet, The*, **2021**, 398, 981-990	40	68
73	The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers. *Clinical Infectious Diseases*, **2021**, 73, e699-e709	11.6	120
72	High flavivirus structural plasticity demonstrated by a non-spherical morphological variant. *Nature Communications*, **2020**, 11, 3112	17.4	8
71	Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines. *Vaccines*, **2020**, 8,	5.3	8
70	Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. *Cell Host and Microbe*, **2020**, 28, 445-454.e6	23.4	187
69	Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel. *Wellcome Open Research*, **2020**, 5, 139	4.8	120

68	SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. *Wellcome Open Research*, **2020**, 5, 181	4.8	38
67	SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020. *Eurosurveillance*, **2020**, 25,	19.8	9
66	Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020. *Eurosurveillance*, **2020**, 25,	19.8	36
65	Differential occupational risks to healthcare workers from SARS-CoV-2 observed during a prospective observational study. *ELife*, **2020**, 9,	8.9	122
64	Author response: Differential occupational risks to healthcare workers from SARS-CoV-2 observed during a prospective observational study **2020**,		4
63	Antibodies targeting epitopes on the cell-surface form of NS1 protect against Zika virus infection during pregnancy. *Nature Communications*, **2020**, 11, 5278	17.4	16
62	Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. *Nature Structural and Molecular Biology*, **2020**, 27, 950-958	17.6	175
61	Broad and strong memory CD4 and CD8 T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. *Nature Immunology*, **2020**, 21, 1336-1345	19.1	615
60	Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. *Lancet Infectious Diseases, The*, **2020**, 20, 1390-1400	25.5	212
59	Autoantibody-dependent amplification of inflammation in SLE. *Cell Death and Disease*, **2020**, 11, 729	9.8	9
58	A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection. *Nature Immunology*, **2019**, 20, 1291-1298	19.1	33
57	Dengue and Zika Virus Cross-Reactive Human Monoclonal Antibodies Protect against Spondweni Virus Infection and Pathogenesis in Mice. *Cell Reports*, **2019**, 26, 1585-1597.e4	10.6	9
56	Longitudinal Analysis of Antibody Cross-neutralization Following Zika Virus and Dengue Virus Infection in Asia and the Americas. *Journal of Infectious Diseases*, **2018**, 218, 536-545	7	95
55	Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Challenges of a Dengue Vaccine. *Cold Spring Harbor Perspectives in Biology*, **2018**, 10,	10.2	12
54	Therapeutic and protective efficacy of a dengue antibody against Zika infection in rhesus monkeys. *Nature Medicine*, **2018**, 24, 721-723	50.5	35
53	The immunology of Zika Virus. *F1000Research*, **2018**, 7, 203	3.6	15
52	Cross-Reactive Bactericidal Antimeningococcal Antibodies Can Be Isolated From Convalescing Invasive Meningococcal Disease Patients Using Reverse Vaccinology 2.0. *Frontiers in Immunology*, **2018**, 9, 1621	8.4	3
51	Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus. *Nature Immunology*, **2018**, 19, 1248-1256	19.1	21

50	The immune response against flaviviruses. *Nature Immunology*, **2018**, 19, 1189-1198	19.1	82
49	Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine. *Journal of Virology*, **2018**, 92,	6.6	15
48	Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors. *Nature Communications*, **2018**, 9, 2441	17.4	51
47	Recent advances in human flavivirus vaccines. *Current Opinion in Virology*, **2017**, 23, 95-101	7.5	33
46	Covalently linked dengue virus envelope glycoprotein dimers reduce exposure of the immunodominant fusion loop epitope. *Nature Communications*, **2017**, 8, 15411	17.4	48
45	Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection. *Nature Immunology*, **2017**, 18, 1261-1269	19.1	74
44	Germline bias dictates cross-serotype reactivity in a common dengue-virus-specific CD8 T cell response. *Nature Immunology*, **2017**, 18, 1228-1237	19.1	22
43	The immunopathology of dengue and Zika virus infections. *Current Opinion in Immunology*, **2017**, 48, 1-6	7.8	22
42	Evolution of neurovirulent Zika virus. *Science*, **2017**, 358, 863-864	33.3	6
41	Endothelial Nitric Oxide Pathways in the Pathophysiology of Dengue: A Prospective Observational Study. *Clinical Infectious Diseases*, **2017**, 65, 1453-1461	11.6	16
40	Synovial IL-21/TNF-producing CD4 T cells induce joint destruction in rheumatoid arthritis by inducing matrix metalloproteinase production by fibroblast-like synoviocytes. *Journal of Leukocyte Biology*, **2017**, 101, 775-783	6.5	22
39	MAIT cells are activated during human viral infections. *Nature Communications*, **2016**, 7, 11653	17.4	283
38	Structural basis of potent Zika-dengue virus antibody cross-neutralization. *Nature*, **2016**, 536, 48-53	50.4	362
37	Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. *Nature Immunology*, **2016**, 17, 1102-8	19.1	637
36	Recent advances in understanding dengue. *F1000Research*, **2016**, 5,	3.6	31
35	Antibodies and tuberculosis. *Tuberculosis*, **2016**, 101, 102-113	2.6	93
34	Microvascular and endothelial function for risk prediction in dengue: an observational study. *Lancet, The*, **2015**, 385 Suppl 1, S102	40	15
33	New insights into the immunopathology and control of dengue virus infection. *Nature Reviews Immunology*, **2015**, 15, 745-59	36.5	212

32	A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. *Nature Immunology*, **2015**, 16, 170-177	19.1	309
31	Recognition determinants of broadly neutralizing human antibodies against dengue viruses. *Nature* , **2015**, 520, 109-13	50.4	234
30	Cardiovascular manifestations of the emerging dengue pandemic. *Nature Reviews Cardiology*, **2014**, 11, 335-45	14.8	70
29	Sensing of immature particles produced by dengue virus infected cells induces an antiviral response by plasmacytoid dendritic cells. *PLoS Pathogens*, **2014**, 10, e1004434	7.6	43
28	Invariant NKT cell response to dengue virus infection in human. *PLoS Neglected Tropical Diseases*, **2014**, 8, e2955	4.8	16
27	A simplified positive-sense-RNA virus construction approach that enhances analysis throughput. *Journal of Virology*, **2013**, 87, 12667-74	6.6	34
26	Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity. *Journal of Immunology*, **2012**, 188, 4971-9	5.3	65
25	An in-depth analysis of original antigenic sin in dengue virus infection. *Journal of Virology*, **2011**, 85, 410-21	4.6	145
24	Cross-reacting antibodies enhance dengue virus infection in humans. *Science*, **2010**, 328, 745-8	33.3	624
23	Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 16922-7	11.5	174
22	T cell responses to whole SARS coronavirus in humans. *Journal of Immunology*, **2008**, 181, 5490-500	5.3	344
21	T cell Responses and Dengue Haemorrhagic Fever. *Novartis Foundation Symposium*, **2008**, 164-176		11
20	The Influence of CD25+ Cells on the Generation of Immunity to Tumour Cell Lines in Mice. *Novartis Foundation Symposium*, **2008**, 149-157		6
19	T cell responses and dengue haemorrhagic fever. *Novartis Foundation Symposium*, **2006**, 277, 164-71; discussion 171-6, 251-3		11
18	HIV-specific cytotoxic T cells from long-term survivors select a unique T cell receptor. *Journal of Experimental Medicine*, **2004**, 200, 1547-57	16.6	96
17	Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. *Nature Medicine*, **2003**, 9, 921-7	50.5	609
16	HIV-1 Nef: negative effector of Fas?. *Nature Immunology*, **2001**, 2, 384-5	19.1	8
15	Complex regulation of tau exon 10, whose missplicing causes frontotemporal dementia. *Journal of Neurochemistry*, **2000**, 74, 490-500	6	68

14	Induction of Fas ligand expression by HIV involves the interaction of Nef with the T cell receptor zeta chain. *Journal of Experimental Medicine*, **1999**, 189, 1489-96	16.6	219
13	Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. *Nature Structural Biology*, **1999**, 6, 1048-53		214
12	Rapid Death of Adoptively Transferred T Cells in Acquired Immunodeficiency Syndrome. *Blood*, **1999**, 93, 1506-1510	2.2	90
11	Rapid Death of Adoptively Transferred T Cells in Acquired Immunodeficiency Syndrome. *Blood*, **1999**, 93, 1506-1510	2.2	14
10	A high resolution view of an adolescent flavivirus		2
9	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses		7
8	A haemagglutination test for rapid detection of antibodies to SARS-CoV-2		6
7	Antibody evasion by the Brazilian P.1 strain of SARS-CoV-2		14
6	An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status		16
5	Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses		6
4	A blood atlas of COVID-19 defines hallmarks of disease severity and specificity		4
3	The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 Beta (B.1.351) and other variants of concern in preclinical studies		8
2	Reduced Neutralization of SARS-CoV-2 B.1.1.7 Variant from Naturally Acquired and Vaccine Induced Antibody Immunity. *SSRN Electronic Journal*,	1	2
1	Further antibody escape by Omicron BA.4 and BA.5 from vaccine and BA.1 serum		3